195 related articles for article (PubMed ID: 28664915)
21. Novel directions in adjuvant chemotherapy for early stage epithelial ovarian cancer.
Sakarya DK; Yetimalar MH; Ozbasar D
Asian Pac J Cancer Prev; 2015; 16(10):4157-60. PubMed ID: 26028065
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
Behbakht K; Sill MW; Darcy KM; Rubin SC; Mannel RS; Waggoner S; Schilder RJ; Cai KQ; Godwin AK; Alpaugh RK
Gynecol Oncol; 2011 Oct; 123(1):19-26. PubMed ID: 21752435
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
24. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
[TBL] [Abstract][Full Text] [Related]
28. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
29. Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
Petrillo M; Amadio G; Salutari V; Paris I; Di Stefano MG; Ferandina G; Scambia G; Fagotti A
Gynecol Oncol; 2016 Aug; 142(2):231-6. PubMed ID: 27215633
[TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
31. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
[TBL] [Abstract][Full Text] [Related]
32. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Lesnock JL; Farris C; Krivak TC; Smith KJ; Markman M
Gynecol Oncol; 2011 Sep; 122(3):473-8. PubMed ID: 21665250
[TBL] [Abstract][Full Text] [Related]
33. iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer.
Pearl ML; Dong H; Zhao Q; Tulley S; Dombroff MK; Chen WT
Gynecol Oncol; 2017 Nov; 147(2):426-432. PubMed ID: 28830645
[TBL] [Abstract][Full Text] [Related]
34. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor.
Bamias A; Sotiropoulou M; Zagouri F; Trachana P; Sakellariou K; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Eur J Cancer; 2012 Jul; 48(10):1476-83. PubMed ID: 22047635
[TBL] [Abstract][Full Text] [Related]
35. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
36. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL; Wang Y; Zhao L; Orlando M; Obasaju CK; Gill JF; Tai DF
Gynecol Oncol; 2011 Dec; 123(3):479-85. PubMed ID: 21978765
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
Fauci JM; Whitworth JM; Schneider KE; Subramaniam A; Zhang B; Frederick PJ; Kilgore LC; Straughn JM
Gynecol Oncol; 2011 Sep; 122(3):532-5. PubMed ID: 21658751
[TBL] [Abstract][Full Text] [Related]
38. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
Bilici A; Salepci T; Dane F; Gumus M; Ustaalioglu BB; Seker M; Salman T; Turan C; Unal O; Yaylaci M
Arch Gynecol Obstet; 2010 Oct; 282(4):417-25. PubMed ID: 20035339
[TBL] [Abstract][Full Text] [Related]
40. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]